Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Associated Disease in Korean Children
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose The myelin oligodendrocyte glycoprotein (MOG) antibody is detected at a high rate in childhood acquired demyelinating syndrome (ADS). This study aimed to determine the diagnostic value of the MOG antibody in ADS and the spectrum of MOGantibody- positive demyelinating diseases in children. Methods This study included 128 patients diagnosed with ADS (n=94) or unexplained encephalitis (n=34). The MOG antibody in serum was tested using an in-house live-cell-based immunofluorescence assay. Results The MOG antibody was detected in 48 patients (46 ADS patients and 2 encephalitis patients, comprising 23 males and 25 females). Acute disseminated encephalomyelitis (ADEM) (35.4%) was the most-common diagnosis, followed by the unclassified form (17.4%), isolated optic neuritis (ON) (15.2%), neuromyelitis optica spectrum disorder (13.0%), multiple sclerosis (MS) (10.8%), other clinically isolated syndromes [monophasic event except ADEM, isolated ON, or transverse myelitis (TM)] (8.7%), and unexplained encephalitis (4.3%). At the initial presentation, 35 out of the 46 patients with ADS had brain lesions detected in magnetic resonance imaging, and 54% of these 35 patients had encephalopathy. Nine of the 11 patients without brain lesions exhibited only ON. Thirty-nine percent of the patients experienced a multiphasic event during the mean follow-up period of 34.9 months (range 1.4–169.0 months). Encephalopathy at the initial presentation was frequently confirmed in the monophasic group (p= 0.011). Conclusions MOG antibodies were identified in all pediatric ADS phenotypes except for monophasic TM. Therefore, the MOG antibody test is recommended for all pediatric patients with ADS, especially before a diagnosis of MS and for patients without a clear diagnosis.
Abstract
Background and Purpose The myelin oligodendrocyte glycoprotein (MOG) antibody is detected at a high rate in childhood acquired demyelinating syndrome (ADS). This study aimed to determine the diagnostic value of the MOG antibody in ADS and the spectrum of MOGantibody- positive demyelinating diseases in children. Methods This study included 128 patients diagnosed with ADS (n=94) or unexplained encephalitis (n=34). The MOG antibody in serum was tested using an in-house live-cell-based immunofluorescence assay. Results The MOG antibody was detected in 48 patients (46 ADS patients and 2 encephalitis patients, comprising 23 males and 25 females). Acute disseminated encephalomyelitis (ADEM) (35.4%) was the most-common diagnosis, followed by the unclassified form (17.4%), isolated optic neuritis (ON) (15.2%), neuromyelitis optica spectrum disorder (13.0%), multiple sclerosis (MS) (10.8%), other clinically isolated syndromes [monophasic event except ADEM, isolated ON, or transverse myelitis (TM)] (8.7%), and unexplained encephalitis (4.3%). At the initial presentation, 35 out of the 46 patients with ADS had brain lesions detected in magnetic resonance imaging, and 54% of these 35 patients had encephalopathy. Nine of the 11 patients without brain lesions exhibited only ON. Thirty-nine percent of the patients experienced a multiphasic event during the mean follow-up period of 34.9 months (range 1.4–169.0 months). Encephalopathy at the initial presentation was frequently confirmed in the monophasic group (p= 0.011). Conclusions MOG antibodies were identified in all pediatric ADS phenotypes except for monophasic TM. Therefore, the MOG antibody test is recommended for all pediatric patients with ADS, especially before a diagnosis of MS and for patients without a clear diagnosis.
참고문헌 (28)
- Hintzen RQ, "Pediatric acquired CNS demyelinating syndromes : features associated with multiple sclerosis", Neurology, 87(9 Suppl 2), pp.S67~S73 (2016)
- Thompson AJ, "Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria", Lancet Neurol, 17, pp.162~173 (2018)
- Krupp LB, "International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions", Mult Scler, 19, pp.1261~1267 (2013)
- Huppke P, "Neuromyelitis optica and NMO-IgG in European pediatric patients", Neurology, 75, pp.1740~1744 (2010)
- Chabas D, "Younger children with MS have a distinct CSF inflammatory profile at disease onset", Neurology, 74, pp.399~405 (2010)
- Di Pauli F, "New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases", Mult Scler Relat Disord, 22, pp.35~37 (2018)
- Wells E, "Neuroimmune disorders of the central nervous system in children in the molecular era", Nat Rev Neurol, 14, pp.433~445 (2018)
- Cobo-Calvo Á, "MOG antibody-related disorders : common features and uncommon presentations", J Neurol, 264, pp.1945~1955 (2017)
- Dale RC, "Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton", Neurol Neuroimmunol Neuroinflamm, 1, pp.e12~ (2014)
- Fernandez-Carbonell C, "Clinical and MRI phenotype of children with MOG antibodies", Mult Scler, 22, pp.174~184 (2016)
- Hacohen Y, "Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children", Neurol Neuroimmunol Neuroinflamm, 2, pp.e81~ (2015)
- Ketelslegers IA, "Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort", Mult Scler, 21, pp.1513~1520 (2015)
- Rostásy K, "Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica", Mult Scler, 19, pp.1052~1059 (2013)
- Baumann M, "Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG):extending the spectrum of MOG antibody positive diseases", Mult Scler, 22, pp.1821~1829 (2016)
- Hamid SHM, "Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease", JAMA Neurol, 75, pp.65~71 (2018)
- Ogawa R, "MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy", Neurol Neuroimmunol Neuroinflamm, 4, pp.e322~ (2017)
- Wang JJ, "Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD", Neurology, 87, pp.229~231 (2016)
- Wingerchuk DM, "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders", Neurology, 85, pp.177~189 (2015)
- Kim Y, "Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases", Mult Scler Relat Disord, 40, pp.101939~ (2020)
- Hennes EM, "Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome", Neurology, 89, pp.900~908 (2017)
- Peschl P, "Myelin oligodendrocyte glycoprotein : deciphering a target in inflammatory demyelinating diseases", Front Immunol, 8, pp.529~ (2017)
- Langer-Gould A, "Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children", Neurology, 77, pp.1143~1148 (2011)
- Hino-Fukuyo N, "Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies", Brain Dev, 37, pp.849~852 (2015)
- Jarius S, "MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome", J Neuroinflammation, 13, pp.280~ (2016)
- Renoux C, "Natural history of multiple sclerosis with childhood onset", N Engl J Med, 356, pp.2603~2613 (2007)
- Waldman A, "Pediatric multiple sclerosis : clinical features and outcome", Neurology, 87(9 Suppl 2), pp.S74~S81 (2016)
- Jurynczyk M, "Clinical presentation and prognosis in MOG-antibody disease : a UK study", Brain, 140, pp.3128~3138 (2017)
- Fujimori J, "Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies", J Neurol Neurosurg Psychiatry, 88, pp.534~536 (2017)